Q-omics provides the consensus-scored NLE1 profile across patient tissues and cancer cell-line models. NLE1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NLE1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, NLE1 protein abundance shows 26,146 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRC, and LSCC as cancer lineages where NLE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLE1 survival associations across molecular data types. NLE1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLE1 RNA expression–survival associations across cancer types. High NLE1 expression shows unfavorable associations in LIHC, ACC, BLCA and KIRP, but favorable associations in SCLC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NLE1 RNA expression.
This table summarizes NLE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NLE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLE1 shows higher tumor expression in KIRC, COAD, KIRP, BLCA, LIHC and STAD. The KIRC box plot shows higher NLE1 RNA expression in tumor versus normal tissue (log2 FC = +0.811, t-test p < 0.001).
This table shows molecular features associated with NLE1 in patient tissues and cancer cell lines. In patient samples, NLE1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NLE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
